Study details
Enrolling now
Empagliflozin Trial to Reduce Arterial Stiffness in Older Adults
University of Missouri-Columbia
NCT IDNCT06506422ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
80
Study length
about 4.5 years
Ages
60–80
Locations
1 site in MO
About this study
Researchers are testing whether empagliflozin, a medication, can help reduce arterial stiffness in older adults. The trial involves randomly assigning participants aged 60-80 to either empagliflozin or a placebo for 12 weeks. It will last approximately 1655 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Empagliflozin 10 MG
- 2.Take Placebo
PhasePhase 2/Phase 3
DrugEmpagliflozin 10 MG
Primary goalCarotid Femoral Pulse Wave Velocity (cfPWV)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Endpoints
Primary: Carotid Femoral Pulse Wave Velocity (cfPWV)